Pfizer settles long-running Nigerian suit for $75M; Moody's rates HCA's debt offering as junk;

> Pfizer has finally dispatched a Nigerian lawsuit over tests of its drug Trovan which has dragged on for more than 10 years. The price: $75 million, including $30 million in healthcare initiatives, $10 million in legal costs and $35 million to study participants. Article

> Moody's Investors Service has assigned a Ba3 rating to HCA's planned $750 million debt offering, putting the chain's debt in junk-bond territory. FierceHealthFinance

> Consumers are getting psyched about the potential benefits of telemedicine, especially remote monitoring of their conditions through telemedical networks. FierceHealthIT

> Over the past three years, the U.S. military has deployed at least 200 robots to remote locations to assist Army doctors. FierceMobileHealthcare

And Finally... Hey, when I'm forced to take a walk on Boardwalk with four hotels on it, I get pretty upset, too. (Well, not that upset.) Article